Phase II study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (NET)

Category Primary study
JournalJournal of Clinical Oncology
Year 2012
This article has no abstract
Epistemonikos ID: 4ac51e7fc7f70c5f61d2c47d4c6704b6baf93247
First added on: Feb 05, 2025